Intelligence · Patents
Patents expiring in 2031
Annual patent cliff calendar for 2031 — US pharmaceutical patents by expiration date.
- Patents
- 902
Quick answer
902 indexed pharmaceutical patents have expiration dates in 2031. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8013152
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 8012739
Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA synthetase pairs
granted -
US 8013015
Small molecule inhibitors of ghrelin O-acyltransferase
granted -
US 8012965
Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
granted -
US 8012490
Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
granted -
US 8012476
Molecules with extended half-lives, compositions and uses thereof
granted -
US 8012730
Specific lysis of staphylococcal pathogens by bacteriophage phi11 endolysin
granted -
US 8012493
Malaria vaccines
granted -
US 8012699
Recombinant antigens for diagnosis and prevention of murine typhus
granted -
US 8012946
Anti-angiogenic methods and compositions
granted -
US 8012976
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
granted -
US 8012955
N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
granted -
US 8013005
Dual-acting antihypertensive agents
granted -
US 8017155
Methods for encapsulation of biomacromolecules in polymers
granted -
US 8017578
Orally active peptides that prevent cell damage and death
granted -
US 8017617
Amidine-containing compounds useful as muscarinic receptor antagonists
granted -
US 8017636
1,2,4-Oxadiazole benzoic acid compositions and their use in bioassays
granted -
US 8017745
Plasmodium falciparum antigens and methods of use
granted -
US 8017762
Modified iRNA agents
granted -
US 8017781
Azaindazoles useful as inhibitors of kinases
granted -
US 8017135
Lipid-drug conjugates for local therapy of eye diseases
granted -
US 8017619
Compositions useful as inhibitors of protein kinases
granted -
US 8017763
Chemically modified oligonucleotides
granted -
US 8017783
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 8017130
Method of accelerated vaccination against Ebola viruses
granted -
US 8017151
Amphiphilic polymer-protein conjugates and methods of use thereof
granted -
US 8017149
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 8017321
Gefitinib sensitivity-related gene expression and products and methods related thereto
granted -
US 8022202
Dihydrodiazepines useful as inhibitors of protein kinases
granted -
US 8022175
Production of anti-peptide monoclonal antibodies to distinguish Exotic New Castle diseases viruses from vaccine strains of Newcastle disease virus
granted -
US 8022041
Prodrug of an ICE inhibitor
granted -
US 8021831
Taxane chemosensitivity prediction test
granted -
US 8021687
Modified release compositions of milnacipran
granted -
US 8021673
Proteins with repetitive Bacterial-Ig-like (Big) domains present in Leptospira species
granted -
US 8021644
Methods for measuring rates of reverse cholesterol transport in vivo, as an index of anti-atherogenesis
granted -
US 8021646
Compositions and methods for magnetic resonance imaging contrast agents
granted -
US 8021671
Pro-apoptotic bacterial vaccines to enhance cellular immune responses
granted -
US 8021874
Very long chain polyunsaturated fatty acids, methods of production, and uses
granted -
US 8022040
Hydroxyapatite-binding peptides for bone growth and inhibition
granted -
US 8022052
Inhibition of PPAR gamma expression by specific osteogenic oxysterols
granted -
US 8022057
MAPK/ERK kinase inhibitors
granted -
US 8022094
Carvedilol phosphate
granted -
US 8022190
Immuno-molecules containing viral proteins, compositions thereof and methods of using
granted -
US 8025887
Avirulent, immunogenic flavivirus chimeras
granted -
US 8026360
Substituted pyridazines as stearoyl-CoA desaturase inhibitors
granted -
US 8026234
Polo-like kinase inhibitors
granted -
US 8026263
Methods for inhibiting neoproliferative changes in blood vessel walls
granted -
US 8026350
Tumor suppressor gene, p28ING5
granted
Frequently asked questions
How many pharma patents expire in 2031?
902 published patents in our USPTO index have expiration dates falling in calendar year 2031.